Purine metabolism (None (purine metabolism is a pathway, not a single molecule or protein, so no standard abbreviation applies))

Purine metabolism encompasses all cellular processes involved in the synthesis, salvage, and degradation of purines—key building blocks required for nucleotides like ATP and GTP. The de novo synthetic branch constructs new purines from small molecules through ten enzymatic steps leading to inosinate monophosphate (IMP), which can be converted into adenosinate monophosphate (AMP) or guanylate monophosphate (GMP). The salvage branch recycles free bases using enzymes like hypoxanthin-guanosin phosphoribosyltransferase. Catabolism ultimately leads to uric acid formation—the end product in humans—which serves both as an antioxidant but also causes gout if accumulated excessively[1][3][5]. Dysregulation or hyperactivity within this network is implicated in several diseases including cancer—where increased nucleotide demand drives upregulation—and metabolic disorders such as gout. Many chemotherapeutics exploit these dependencies by inhibiting key steps within the de novo branch; similarly, drugs like allopurinol treat hyperuricemia by blocking uric acid production at the level of xanthin oxidoreductase/xanthin oxidase[2][3]. Because "purine metabolism" refers collectively to many molecules rather than one discrete targetable entity, it should not be considered a canonical drug target itself but rather describes an important biological process/pathway relevant across multiple therapeutic areas[1].

Other names

Purine biosynthesis and degradationPurine metabolic pathwayDe novo purine synthesisPurine salvage pathway

Inhibition of nucleotide biosynthesis to limit DNA/RNA replication in rapidly dividing cells/cancer cells. Inhibition of xanthine oxidoreductase to reduce uric acid formation. Disruption/modulation of immune cell proliferation by limiting nucleotide availability.